Inhibition of inflammation

The term "Inhibition of inflammation" does not denote a distinct molecule, receptor, or drug target. Rather, it describes a therapeutic concept encompassing many distinct biological pathways and molecular mechanisms. Numerous proteins (such as interleukin-1 receptor-associated kinase 4, NLRP3 inflammasome components, IL-1β, cytokine receptors, and others) and drug classes (such as monoclonal antibodies against cytokines, inflammasome inhibitors, and classical anti-inflammatory drugs) have been developed to inhibit various aspects of the inflammatory response[1][2][3][4][5][7]. This non-specific term should be replaced with a precise molecular target (for example, "Interleukin-1 receptor-associated kinase 4" or "NLRP3 inflammasome") to support structured drug discovery and pharmacological profiling.